Blog

Douglas Flora: What began as a journal has evolved into something far more meaningful

Douglas Flora/LinkedIn

Jan 10, 2025, 15:30

Douglas Flora: What began as a journal has evolved into something far more meaningful

Douglas Flora, Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, shared a post on LinkedIn:

“‘The capacity to learn is a gift; the ability to learn is a skill; the willingness to learn is a choice.’ — Brian Herbert.

There’s something distinctly satisfying about holding the latest print copy of AI in Precision Oncology.

The December issue highlights important research that bridges the gap between AI’s potential and real clinical impact in cancer care.

Inside, you’ll find teams challenging conventional approaches – developing AI solutions that could transform how we treat patients tomorrow.

From novel biomarker detection to treatment response prediction, each peer-reviewed article pushes us closer to more precise, personalized oncology care.

I’m grateful to Azra AI and AstraZeneca their early support of our vision and this young title. Let me know if YOUR team wants to be involved in future issues.

The team at Mary Ann Liebert, Inc are great partners, with a full-service shop.

What began as a journal has evolved into something far more meaningful: a community of forward-thinking clinicians and researchers who believe in better cancer care.

Whether you’re a veteran oncologist or new to the field, you’ll find insights here that challenge and inspire.

What’s catching your attention in AI and oncology lately? Share your thoughts below – your perspective matters.

Ready to dive in?

Current subscribers: Your December issue is on its way

New readers.”

Douglas Flora

Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health and the Leader of the AI and HealthCare Team for the Cincinnati AI Catalyst (CaiC).

As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.